Seminars in Oncology
Volume 33 , Pages 3-8 , June 2006

New Therapies in the Treatment of Breast Cancer

  • Vivek Roy
    • ,
  • Edith A. Perez

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Edith A. Perez, MD, Hematology-Oncology Department, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.

References 

  1. Surveillance, Epidemiology, and End Results (SEER) Database. Available at: http://www.seer.cancer.gov/statfacts/html/breast.html (accessed April 27, 2006)
  2. Howell A , Cuzick J , Baum M , et al.   Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer . Lancet . 2005;365:60–62
  3. Ingle J , Rowland K , Suman V , et al.   Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy (A phase II trial of the North Central Cancer Treatment Group) . Breast Cancer Res Treat . 2004;88:409; abstr
  4. Jelovac D , Macedo L , Goloubeva O , et al.   Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model . Cancer Res . 2005;65:5439–5444
  5. Aun B , Dice K , Albarracin C , et al.   The combination of letrozole and imatinib mesylate for metastatic breast cancer . Breast Cancer Res Treat . 2004;88:6046; abstr
  6. Awada A , Cardoso F , Fontaine C , et al.   A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole . Breast Cancer Res Treat . 2004;88:6043; abstr
  7. Chu Q , Cianfrocca M , Murray N , et al.   A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients . Breast Cancer Res Treat . 2004;88:6044; abstr
  8. O’Shaughnessy J , Miles D , Vukelja S , et al.   Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer (Phase III trial results) . J Clin Oncol . 2002;20:2812–2823
  9. Albain K , Nag S , Calderillo-Ruiz G , et al.   Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC) (First report of overall survival) . Proc Am Soc Clin Oncol . 2004;22:510; abstr
  10. Jones SE , Erban J , Overmoyer B , et al.   Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer . J Clin Oncol . 2005;23:5542–5551
  11. Perez EA , Hillman DW , Stella PJ , et al.   A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma . Cancer . 2000;88:124–131
  12. Perez EA , Suman VJ , Fitch TR , et al.   A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer (NCCTG study N9932) . Oncology . 2005;69:117–121
  13. Decatris MP , Sundar S , O’Byrne KJ . Platinum-based chemotherapy in metastatic breast cancer (Current status) . Cancer Treat Rev . 2004;30:53–81
  14. Perez EA . Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes . Clin Breast Cancer . 2004;4(suppl 3):S113–S116
  15. Sparreboom A , van Zuylen L , Brouwer E , et al.   Cremophor EL-mediated alteration of paclitaxel distribution in human blood (Clinical pharmacokinetic implications) . Cancer Res . 1999;59:1454–1457
  16. John TA , Vogel SM , Tiruppathi C , et al.   Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer . Am J Physiol Lung Cell Mol Physiol . 2003;284:L187–L196
  17. Ibrahim NK , Samuels B , Page R , et al.   Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer . J Clin Oncol . 2005;23:6019–6026
  18. Gradishar WJ , Tjulandin S , Davidson N , et al.   Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer . J Clin Oncol . 2005;23:7794–7803
  19. Lee FYF , Borzilleri R , Fairchild CR , et al.   BMS-247550 (A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy) . Clin Cancer Res . 2001;7:1429–1437
  20. Low JA , Wedam SB , Lee JJ , et al.   Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B Analog, in metastatic and locally advanced breast cancer . J Clin Oncol . 2005;23:2726–2734
  21. Bennouna J , Campone M , Delord J , et al.   Vinflunine (A novel antitubulin agent in solid malignancies) . Expert Opin Investig Drugs . 2005;14:1259–1267
  22. Fumoleau P , Campone M , Vorobiof D , et al.   Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure . Proc Am Soc Clin Oncol . 2004;22:542; abstr
  23. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  24. Miller KD , Chap LI , Holmes FA , et al.   Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer . J Clin Oncol . 2005;23:792–799
  25. Miller K , Wang M , Gralow J , et al.   A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (A trial coordinated by the Eastern Cooperative Oncology Group (E2100)) . 2003; Proceedings from the 28th annual San Antonio Breast Cancer Symposium. (abstr 3)
  26. Dupont J , Schwartz L , Koutcher J , et al.   Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies . Proc Am Soc Clin Oncol . 2004;22:3009; abstr
  27. Dupont J , Rothenberg ML , Spriggs DR , et al.   Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors . Proc Am Soc Clin Oncol . 2005;23:3029; abstr
  28. Miller KD , Burstein HJ , Elias A , et al.   Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) . Proc Am Soc Clin Oncol . 2005;23:563; abstr
  29. Suttle AB , Hurwitz H , Dowlati A , et al.   Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors . Proc Am Soc Clin Oncol . 2004;22:3054; abstr
  30. Yarden Y , Sliwkowski MX . Untangling the ErbB signalling network . Nat Rev Mol Cell Biol . 2001;2:127–137
  31. Slamon DJ , Leyland-Jones B , Shak S , et al.   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 . N Engl J Med . 2001;344:783–792
  32. Romond EH , Perez EA , Bryant J , et al.   Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N Engl J Med . 2005;353:1673–1684
  33. Roche PC , Suman VJ , Jenkins RB , et al.   Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 . J Natl Cancer Inst . 2002;94:855–857
  34. Baselga J , Carbonell X , Castaneda-Soto N-J , et al.   Updated efficacy and safety analyses of 3-weekly Herceptin monotherapy in women with HER2-positive metastatic breast cancer (Results from twelve months of follow-up to a phase II study) . Breast Cancer Res Treat . 2004;88:3042; abstr
  35. O’Shaughnessy JA , Vukelja S , Marsland T , et al.   Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer . Clin Breast Cancer . 2004;5:142–147
  36. Burstein HJ , Harris LN , Marcom PK , et al.   Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer (multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm) . J Clin Oncol . 2003;21:2889–2895
  37. Pegram MD , Konecny GE , O’Callaghan C , et al.   Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer . J Natl Cancer Inst . 2004;96:739–749
  38. Agus DB , Gordon M , Taylor C , et al.   Clinical activity in a phase I trial of HER-2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST) . Proc Am Soc Clin Oncol . 2003;22:192; abstr
  39. Attard G , Kitzen JJ , de Bono J , et al.   A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors . Proc Am Soc Clin Oncol . 2005;23:3166; abstr
  40. Cortes J , Baselga J , Kellokumpu-Lehtinen K , et al.   Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 . Proc Am Soc Clin Oncol . 2005;23:3068; abstr
  41. Burris HA . Dual kinase inhibition in the treatment of breast cancer (Initial experience with the EGFR/ErbB-2 inhibitor lapatinib) . Oncologist . 2004;9(suppl 3):10–15
  42. Gomez H , Chavez M , Doval D , et al.   A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer . Proc Am Soc Clin Oncol . 2005;23:3046; abstr
  43. Moore M , Goldstein D , Hamm J , et al.   Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] . Proc Am Soc Clin Oncol . 2005;23:1; abstr
  44. Graham D , Hillman D , Hobday TJ , et al.   N0234 (Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)) . Proc Am Soc Clin Oncol . 2005;23:644; abstr
  45. Johnston SR , Hickish T , Ellis P , et al.   Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer . J Clin Oncol . 2003;21:2492–2499
  46. Ellis CA , Vos MD , Wickline M , et al.   Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines . Breast Cancer Res Treat . 2003;78:59–67
  47. Johnston SR , Head J , Pancholi S , et al.   Integration of signal transduction inhibitors with endocrine therapy (An approach to overcoming hormone resistance in breast cancer) . Clin Cancer Res . 2003;9:524–532
  48. Lebowitz PF , Eng-Wong J , Widemann BC , et al.   A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer . Clin Cancer Res . 2005;11:1247–1252
  49. Wilhelm S , Carter C , Tang L , et al.   BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis . Cancer Res . 2004;64:7099–7109
  50. Yu K , Toral-Barza L , Discafani C , et al.   mTOR, a novel target in breast cancer (The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer) . Endocr Relat Cancer . 2001;8:249–258
  51. Carraway H , Hidalgo M . New targets for therapy in breast cancer (Mammalian target of rapamycin (mTOR) antagonists) . Breast Cancer Res . 2004;6:219–224
  52. Chan S , Scheulen M , Johnston S , et al.   Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens . Proc Am Soc Clin Oncol . 2003;22:193; abstr

 Dr Roy has received research grant support from Sanofi-Aventis, Celgene, and Cephalon. Dr Perez has received research grant support from Genentech, Pfizer, Eli Lilly and Company, and AstraZeneca.

PII: S0093-7754(06)00138-2

doi: 10.1053/j.seminoncol.2006.03.018

Seminars in Oncology
Volume 33 , Pages 3-8 , June 2006

Article Tools